NASDAQ: NGENNervgen Pharma Corp Stock
$1.78+0.02 (+1.14%)
Updated Oct 2, 2026
NGEN Price
$1.78
Fair Value Price
$0.21
Market Cap
$189.41M
52 Week Low
$1.58
52 Week High
$5.97
P/E
-3.22x
P/B
15.27x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$43.63M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
4.22
Operating Cash Flow
N/A
Beta
1.54
Next Earnings
Nov 12, 2026
Ex-Dividend
N/A
Next Dividend
N/A
NGEN Overview
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NGEN's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -12.86% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NGEN
Ranked#436 of 461
Ranked#436 of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.51 | A | |
| $8.54 | A | |
| $358.07 | A |
Be the first to know about important NGEN news, forecast changes, insider trades & much more!
NGEN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NGEN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NGEN ($1.78) is overvalued by 732.12% relative to our estimate of its Fair Value price of $0.21 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NGEN ($1.78) is not significantly undervalued (732.12%) relative to our estimate of its Fair Value price of $0.21 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NGEN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NGEN due diligence checks available for Premium users.
Valuation
NGEN fair value
Fair Value of NGEN stock based on Discounted Cash Flow (DCF)
Price
$1.78
Fair Value
$0.21
Overvalued by
732.12%
NGEN ($1.78) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NGEN ($1.78) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NGEN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NGEN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.22x
Industry
12.21x
Market
49.66x
NGEN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
15.27x
Industry
5.04x
NGEN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NGEN's financial health
Profit margin
Revenue
$0.0
Net Income
-$20.6M
Profit Margin
0%
Assets to liabilities
Assets
$63.5M
Liabilities
$51.3M
Debt to equity
4.22
NGEN's short-term assets ($64.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NGEN's short-term assets ($64.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NGEN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.0M
Investing
$0.0
Financing
$55.0M
NGEN vs Biotech Stocks
Nervgen Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.